Search - tctmd.com

Displaying 21 - 34 of 34

Sort: Relevancy | Date

News Daily News

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

Caitlin E. Cox

June 25, 2020

News Conference News ACC 2020

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

L.A. McKeown

April 02, 2020

News Daily News

Outcome Differences Between Men and Women With PAD: EUCLID Insights

L.A. McKeown

February 11, 2020

News Conference News ISET 2020

PERT Data Emerge, Though the Exact Strategy Isn’t a Done Deal

Caitlin E. Cox

January 30, 2020

News Conference News AHA 2019

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Shelley Wood

November 18, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

News Daily News

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

Yael L. Maxwell

June 08, 2018

News Industry News

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

January 29, 2018

News Daily News

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

L.A. McKeown

January 02, 2018

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Daily News

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

Caitlin E. Cox

February 08, 2016

News Daily News

双联抗血小板治疗与高危PAD患者的更佳结果有联系

Leah Lawrence

April 29, 2015

News Daily News

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

Leah Lawrence

April 29, 2015

News Daily News

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Yael L. Maxwell

April 26, 2013

Advertisement

Rivaroxaban May Yet Protect After a Hospital Stay: MARINER

New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy

Outcome Differences Between Men and Women With PAD: EUCLID Insights

PERT Data Emerge, Though the Exact Strategy Isn’t a Done Deal

Lower Cholesterol Cuts CV Events: Treat Stroke to Target Trial

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Platelet Reactivity Linked With Ischemic Stroke Risk Post-DES Implantation: ADAPT-DES Substudy

New Real-World Analysis Finds Lower Risk of Major Bleeding and Similar Risk of Stroke with Standard Dose of Pradaxa® Compared to Rivaroxaban in NVAF Patients Newly Initiating Treatment

NOACs May Carry Lower Risk of Intraocular Hemorrhage Than Warfarin

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

他汀类药物可能会保护无症状 PAD 患者免于死亡、心血管事件

双联抗血小板治疗与高危PAD患者的更佳结果有联系

Dual Antiplatelet Therapy Tied to Better Outcomes in High Risk PAD Patients

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content